The US Food and Drug Administration is considering shifting its blood donation policy away from blanket assessments toward questionnaires that focus more on individual risk
The agency is using data from a donor eligibility study and other blood surveillance information that “will likely support a policy transition to individual risk-based donor screening questions for reducing the risk of HIV transmission,” the FDA said in a statement. “The FDA remains committed to gathering the scientific data related to alternative donor deferral policies that maintain a high level of blood safety,” the statement says.
“As LGBTQ leaders and medical experts have been saying for years: bans and restrictions on blood donations from gay and bisexual men are rooted in stigma, not science,” Ellis said. American Medical Association President Dr. Jack Resneck Jr. told CNN in a statement that news of a possible guidelines shift is “encouraging.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Mark Cuban’s prescription drug company in talks with hospitals to fill drug shortagesThe U.S. Food and Drug Administration maintains a list of 185 drugs in short supply.
Les mer »
DOJ: Bothell drug dealer sentenced 10 years for involvement in 2020 drug ring takedownA Bothell man who was involved in a major drug ring bust in 2020 was sentenced to 10 years in prison on Tuesday, according to the U.S. Department of Justice (DOJ). FOX13
Les mer »
'Food for all': MSU Denver opens Rowdy's Corner to expand food options, fight stigmaMetropolitan State University Denver is taking steps to tackle hunger and fight the stigma of asking for help through its new and expanded campus food pantry.
Les mer »
Philly hopes FDA proposal that limits nicotine levels in cigarettes helps city curb smokingThe Food and Drug Administration recently proposed a plan that would set maximum nicotine levels for all cigarettes produced in the U.S. by early next year.
Les mer »
Nestlé may shuck peanut allergy drug at center of $2.6 billion Aimmune acquisition - San Francisco Business TimesThe food giant saw Aimmune as a potential $1 billion food allergy brand, but the rollout of the peanut allergy drug was hurt in part by Covid-19 restrictions.
Les mer »